What is the recommended treatment and dosage for type 2 diabetes using Metformin (biguanide)?

Metformin Treatment for Type 2 Diabetes

First-Line Recommendation

Metformin should be initiated as the first-line pharmacologic agent for type 2 diabetes at a starting dose of 500 mg once or twice daily with meals, titrated by 500 mg weekly to a target dose of 1000 mg twice daily (maximum 2000-2550 mg/day), provided eGFR is ≥45 mL/min/1.73 m². 1, 2

---

Initial Dosing and Titration Strategy

Starting Dose

• Begin with 500 mg once or twice daily with meals to minimize gastrointestinal side effects, which are the most common adverse reactions limiting metformin use 3, 2, 4
• Extended-release formulations can be started at 500 mg once daily with the evening meal for improved tolerability and adherence 3, 2

Titration Protocol

• Increase by 500 mg increments every 7 days until target dose is reached 2
• If gastrointestinal symptoms occur during titration, decrease to the previous lower dose and attempt advancement later 2
• Target dose is typically 1000 mg twice daily for immediate-release or 2000 mg once daily for extended-release formulations 2, 4
• Maximum FDA-approved dose is 2550 mg daily in divided doses, though most patients achieve adequate control at 2000 mg daily 2, 5

---

Renal Function Considerations (Critical Safety Parameters)

eGFR-Based Dosing Algorithm

• eGFR ≥60 mL/min/1.73 m²: Continue standard dosing up to 2000-2550 mg daily 1, 2
• eGFR 45-59 mL/min/1.73 m²: Continue current dose but reassess benefits/risks; do not initiate metformin in this range 1, 2
• eGFR 30-44 mL/min/1.73 m²: Reduce dose to 1000 mg daily (half the standard dose) 1, 2
• eGFR <30 mL/min/1.73 m²: Metformin is contraindicated—discontinue immediately 1, 5

Monitoring Requirements

• Monitor eGFR at least annually in patients with normal renal function 2
• Increase monitoring frequency to every 3-6 months when eGFR <60 mL/min/1.73 m² 1, 2
• Temporarily discontinue metformin before iodinated contrast procedures in patients with eGFR 30-60 mL/min/1.73 m² 1, 3

---

Expected Efficacy

• Metformin reduces HbA1c by 1.0-1.5% compared to placebo 1, 4, 6
• In Chinese patients with type 2 diabetes, metformin decreases HbA1c by 0.7-1.0% 1
• Metformin is weight neutral or promotes modest weight reduction, unlike sulfonylureas or insulin 4, 6
• The UKPDS demonstrated a 36% reduction in all-cause mortality and 39% reduction in myocardial infarction in obese patients with type 2 diabetes treated with metformin 1, 6

---

Managing Gastrointestinal Side Effects

Prevention Strategies

• Start with low dose (500 mg once or twice daily) and titrate gradually 3, 2
• Take metformin with meals to reduce GI symptoms 2, 4
• Consider extended-release formulations, which significantly reduce GI side effects while maintaining efficacy 3, 2

Common GI Symptoms

• Abdominal discomfort, bloating, and diarrhea occur frequently but usually resolve with continued use 3, 4
• If symptoms persist, reduce to previous tolerated dose and advance more slowly 2

---

Additional Monitoring and Safety Considerations

Vitamin B12 Deficiency

• Long-term metformin use may cause vitamin B12 deficiency 1, 3, 4
• Check vitamin B12 levels periodically, especially in patients treated for >4 years or those with anemia or peripheral neuropathy 3, 2
• Supplement with vitamin B12 if deficiency is detected 3

Absolute Contraindications

• eGFR <30 mL/min/1.73 m² 1, 5
• Severe hepatic impairment 1, 5
• Acute or chronic metabolic acidosis 5
• Severe infection, hypoxia, or conditions predisposing to lactic acidosis 1, 4
• Alcohol abuse 4

Temporary Discontinuation Required

• Before major surgery 1
• During acute illness that may compromise renal or hepatic function 3, 2
• Before iodinated contrast procedures (in patients with eGFR 30-60 mL/min/1.73 m²) 1

---

Combination Therapy Considerations

When to Add Second Agent

• If glycemic targets are not achieved after 3 months at maximum tolerated metformin dose, add a second agent rather than delaying intensification 2
• Continue metformin when adding other agents, including insulin, as long as it remains tolerated and not contraindicated 2

Preferred Add-On Agents for High-Risk Patients

• For patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease (eGFR ≥30), add an SGLT2 inhibitor or GLP-1 receptor agonist with proven cardiovascular benefit 1, 2
• These agents reduce risks of CKD progression, cardiovascular events, and hypoglycemia 1

---

Special Populations

Pediatric Patients (10-16 years)

• Safety and effectiveness established in children ≥10 years old 5
• Maximum recommended dose is 2000 mg daily in divided doses 2, 5

Elderly Patients

• Start at the low end of the dosing range due to higher risk of decreased renal function 5
• Assess renal function more frequently in elderly patients 5

Pregnancy and Lactation

• Metformin is present in human milk at low levels (0.11-1% of maternal weight-adjusted dose) 5
• May result in ovulation in anovulatory premenopausal women—discuss contraception 5

---

Critical Pitfalls to Avoid

• Never initiate metformin if eGFR <45 mL/min/1.73 m²—this is a common prescribing error 1, 2
• Do not continue metformin if eGFR falls below 30 mL/min/1.73 m²—risk of lactic acidosis increases substantially 1, 5
• Do not skip renal function monitoring—failure to monitor eGFR can lead to dangerous accumulation 2
• Do not ignore vitamin B12 levels in long-term users, especially those with neuropathy symptoms 3, 2
• Do not delay adding cardioprotective agents (SGLT2i or GLP-1 RA) in patients with established cardiovascular disease or CKD 1, 2